The American Society of Clinical Oncology (ASCO) Annual Meeting is a pivotal event for oncology professionals, and ASCO 2025, happening…
Browsing: sacituzumab govitecan
In the ever-evolving world of oncology, there is always a beacon of hope on the horizon. The latest such promise…
TROPiCS-02 Trial: The TROPiCS-02 trial showcases the potential of Sacituzumab Govitecan, a Trop-2 directed antibody-drug conjugate, as a promising treatment…
Manojkumar Bupathi, MD, MS, from Rocky Mountain Cancer Centers, conducted a safety analysis on cohort 1 of the TROPHY-U-01 phase…
Insights on Breast Cancer Treatment: Yuan Yuan, MD’s Discussion on Sacituzumab Govitecan and Other Novel Treatments By Yuan Yuan, MD,…
Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the patient-reported outcomes from the…
iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Sara Tolaney vs Chemo TROPiCS-02 By Sara Tolaney, MD What were the…
Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with…
iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results…
Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with…
Overview of the ASCENT Trial and Trodelvy The ASCENT Trial (NCT02574455) is a Phase III study that compares Trodelvy (Sacituzumab…
In this episode of The Onco’Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland…